Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cures Excitement May Wane While Senate Works

This article was originally published in The Pink Sheet Daily

Executive Summary

Senate Health Committee continues work on its own 21st Century Cures-related legislation, meaning the newly passed House bill will be out of the spotlight for a bit.

You may also be interested in...



User Fee Bill Could Become Ensnared In US Abortion Politics

Amendment defunding Planned Parenthood is one ACA repeal refugee that could hitch a ride with user fee bill, which would be 'problematic,' to say the least, for Democrats.

US FDA Getting More Money Up Front Under Cures Bill Revisions

Additional funding would arrive beginning in FY 2017 as House pushes bill to Senate.

Senators Circulate Plan For Stand-alone FDA Diagnostics Center, ‘In Vitro Clinical Test’ Rules

Senators are drafting legislation to create a stand-alone FDA Center to oversee diagnostics, including IVDs and LDTs, under a framework distinct from current medical device regulations.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS078676

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel